Medicare could save up to $73bn over 10 years by implementing a new policy dictating that a portion of the prescription drug rebates negotiated on behalf of Part D plans is passed along to reduce beneficiary cost sharing at the point-of-sale, the Pharmaceutical Research and Manufacturers of America argues in Jan. 16 comments to the Centers for Medicare and Medicaid Services.
The comments strongly support passing through a portion of negotiated rebates in Part D, an idea that the industry has been promoting for several months as a remedy for high...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?